Pilot Evaluation of Fecal Immunologic Test (FIT) in Ontario
Prior to implementation of new colorectal cancer (CRC) screening technology (fecal immunochemical test - FIT) in Ontario, there is a need for a laboratory and field assessment to validate and optimize its use in the Ontario climate and conditions (e.g., large geographic area) and to determine whether adjustments to the current structure of the ColonCancerCheck (CCC) Program would be required.
This study consists of 2 phases. Phase 1 consists of laboratory testing of FIT kits to evaluate analytical performance relevant to the requirements of the CCC Program. Phase 2 is a field assessment to evaluate the effect of different distribution and return methods and pre-labeling of kits on uptake and completion of the tests. The entire study will take 12-18 months to complete, with patients being recruited through family physicians in patient enrollment model (PEM) family practices across the province of Ontario.
This Clinical Trials registration relates to Phase 2 of the study.
Study Overview
Status
Conditions
Detailed Description
In 2008 Ontario launched the ColonCancerCheck (CCC) Program, an organized colorectal cancer (CRC) screening program in which average risk patients are offered an at-home screening test and increased risk patients are offered colonoscopy directly through their family physician.
Currently, Ontario's CCC Program utilizes guaiac fecal occult blood testing (gFOBT) in persons at average risk of CRC. However, the program is currently considering a change to fecal immunochemical testing (FIT).
FIT, which comes in quantitative and qualitative formats, is superior to the gFOBT from a scientific perspective because it specifically detects human hemoglobin. gFOBT uses an indirect detection which depends on a peroxidase reaction not specific for human hemoglobin. FIT methodology is also both more convenient and superior from a participant perspective and multiple studies have demonstrated higher participation rates and improved detection of CRC precursors as well as invasive CRCs with FIT compared to gFOBT.
Organized CRC screening programs considering quantitative FIT face certain additional challenges, including uncertain stability over time and tolerance to variation in temperature following sample collection and prior to arrival in a testing laboratory. Prior to implementation of FIT in Ontario, there is a need for a laboratory and field assessment to validate and optimize its use in the Ontario climate and conditions (e.g., large geographic area) and to determine whether adjustments to the current structure of the CCC Program would be required.
This study consists of 2 phases. Phase 1, laboratory testing, assesses 2 quantitative and 3 qualitative FIT kits to evaluate analytical performance relevant to the requirements of the CCC Program. Phase 2 is a field assessment to evaluate the effect of different distribution and return methods and pre-labeling of kits on uptake and completion of the tests. The entire study will take 12-18 months to complete, with patients being recruited through family physicians in patient enrollment model (PEM) family practices across the province of Ontario. Data collection will take place for 6 months, starting on the day that screening kits and/or invitation letters are mailed to patients.
This Clinical Trials registration relates to Phase 2 of the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- Dr. Jill Tinmouth
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Physician in Ontario with a patient enrollment model
- patient: 50-74, Ontario resident, enrolled with physician
Exclusion Criteria:
- patient: no personal or first degree relative family history of CRC, no FOBT within prior 5 years, colonoscopy within past 10 years, FOBT within past 2 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Mail-out/Mail-back
Mailing of FIT kit directly to patient.
Mailing completed kits in for processing.
|
Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
Patients mails completed kit in for processing using postage-paid reply envelope provided.
|
|
Experimental: Mail-out/Drop-off
Mailing of FIT kit directly to patient.
Dropping completed kits at lab for processing.
|
Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
Patient takes completed FIT in to lab patient service centre for processing.
|
|
Experimental: Pick-up/Mail-back
Mailed invitation to pick up lab requisition and then kit.
Mailing completed kits in for processing.
|
Patients mails completed kit in for processing using postage-paid reply envelope provided.
Patients receives a mailed invitation to visit their physician to discuss CRC screening.
At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
|
|
Experimental: Pick-up/Drop-off
Mailed invitation to pick up lab requisition and then kit.
Dropping completed kits at lab for processing.
|
Patient takes completed FIT in to lab patient service centre for processing.
Patients receives a mailed invitation to visit their physician to discuss CRC screening.
At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
FIT Kit uptake
Time Frame: September 2012 to April 2013
|
Comparing FIT kit uptake by patients invited to complete fecal occult blood screening for colorectal cancer using a Fecal Immunochemical Test (FIT), and provided with different kit distribution and return methods.
|
September 2012 to April 2013
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rejection rates
Time Frame: September 2012 to April 2013
|
Assessing the impact of pre-labeling of FIT Kit collection vials with patient name and date of birth, compared to allowing hand-written labeling, on rates of kit rejection at the lab.
|
September 2012 to April 2013
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jill Tinmouth, MD, PhD, Sunnybrook Research Institute
- Principal Investigator: Linda Rabeneck, MD, MPH, Cancer Care Ontario
- Principal Investigator: Lawrence Paszat, MD, SM, Institute for Clinical Evaluative Studies (ICES)
- Principal Investigator: Nancy Baxter, MD, PhD, St. Michaels Hospital
- Principal Investigator: Edward Randall, PhD, DCC, Eastern Health
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 209-2011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.